Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level903 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 |
| Jan 22, 2020 |
| clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01240304 | A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | University of ArkansasOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02570711 | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | terminated | Phase 2 | 3 | Acerta Pharma BVINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | terminated | Phase 2 | 9 | CCTU- Cancer ThemeOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01313416 | Gemcitabine and CT-011 for Resected Pancreatic Cancer | terminated | Phase 2 | 2 | Augusta UniversityOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery | terminated | Phase 2 | 8 | Eben RosenthalOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies | terminated | Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | terminated | Phase 2 | 17 | Beth Israel Medical CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy | terminated | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01632306 | A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00276744 | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | terminated | Phase 2 | 249 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT00868114 | Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer | terminated | Phase 2 | 24 | Leo W. Jenkins Cancer CenterOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT01621243 | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 128 | Momenta Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 29, 2018 | clinicaltrials |
| NCT02241551 | Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 2 | Nathan Bahary, MDOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02767752 | Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer(CHIPAC) | terminated | Phase 2 | 21 | Herlev HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | terminated | Phase 1 / Phase 2 | 81 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00889187 | Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01851174 | Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer | terminated | Phase 2 | 15 | Western Regional Medical CenterOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00426127 | Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 2 | University of IowaOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00262951 | Chemoradiation in Locally Advanced Pancreatic Cancer | terminated | Phase 2 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01056601 | Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | terminated | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00463840 | Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT01688336 | FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 9 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT01531712 | Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable | terminated | Phase 2 | 6 | Institut Català d'OncologiaOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01515046 | Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer(PACMAN-II) | terminated | Phase 2 | 1 | Joseph J. CullenOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT00841035 | 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients | terminated | Phase 2 | 6 | University of Alabama at BirminghamOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT02243007 | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer | terminated | Phase 2 | 7 | Massachusetts General HospitalOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00609765 | Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | terminated | Phase 1 / Phase 2 | 6 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT01108458 | A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma | terminated | Phase 2 | 1 | George Albert FisherOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00470535 | Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer | terminated | Phase 2 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT02242409 | Study of Gemcitabine and Abraxane for Pancreas Cancer | terminated | Phase 2 | 4 | Georgetown UniversityOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01050426 | A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)(PERU) | terminated | Phase 2 | 17 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00726037 | A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer | terminated | Phase 2 | 7 | Loyola UniversityOTHER | 1 | Sep 29, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jan 28, 2020source: clinicaltrials